These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 16353925)

  • 1. Population pharmacokinetic studies in pediatrics: issues in design and analysis.
    Meibohm B; Läer S; Panetta JC; Barrett JS
    AAPS J; 2005 Oct; 7(2):E475-87. PubMed ID: 16353925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development.
    Yellepeddi V; Rower J; Liu X; Kumar S; Rashid J; Sherwin CMT
    Clin Pharmacokinet; 2019 Jan; 58(1):1-13. PubMed ID: 29777528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line?
    Johnson TN; Ke AB
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S83-S93. PubMed ID: 34185901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric Dose Selection for Therapeutic Proteins.
    Malik PRV; Temrikar ZH; Chelle P; Edginton AN; Meibohm B
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S193-S206. PubMed ID: 34185910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Clinical Trial Simulations to Compare the Performance of Different Approaches for Population Analyses of Pediatric Pharmacokinetic Data.
    Temrikar Z; Muensterman E; Engelhardt B; Mohamed MF
    J Clin Pharmacol; 2023 Jul; 63(7):859-868. PubMed ID: 36905228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of covariance between random effects in design for nonlinear mixed-effect models with an illustration in pediatric pharmacokinetics.
    Dumont C; Chenel M; Mentré F
    J Biopharm Stat; 2014; 24(3):471-92. PubMed ID: 24697342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knowledge-driven approaches for the guidance of first-in-children dosing.
    Edginton AN
    Paediatr Anaesth; 2011 Mar; 21(3):206-13. PubMed ID: 21129100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of modeling and simulation in pediatric investigation plans.
    Manolis E; Osman TE; Herold R; Koenig F; Tomasi P; Vamvakas S; Saint Raymond A
    Paediatr Anaesth; 2011 Mar; 21(3):214-21. PubMed ID: 21244569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling.
    Bouzom F; Walther B
    Fundam Clin Pharmacol; 2008 Dec; 22(6):579-87. PubMed ID: 19049658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.
    Dumont C; Mentré F; Gaynor C; Brendel K; Gesson C; Chenel M
    Clin Pharmacokinet; 2013 Jan; 52(1):43-57. PubMed ID: 23212609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric Development of Bosentan Facilitated by Modeling and Simulation.
    Zisowsky J; Géhin M; Kusic-Pajic A; Krause A; Beghetti M; Dingemanse J
    Paediatr Drugs; 2017 Apr; 19(2):121-130. PubMed ID: 28078552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development.
    Wang K; Jiang K; Wei X; Li Y; Wang T; Song Y
    AAPS PharmSciTech; 2021 Jul; 22(6):208. PubMed ID: 34312742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Trial Simulations and Pharmacometric Analysis in Pediatrics: Application to Inhaled Loxapine in Children and Adolescents.
    Dong M; Fukuda T; Selim S; Smith MA; Rabinovich-Guilatt L; Cassella JV; Vinks AA
    Clin Pharmacokinet; 2017 Oct; 56(10):1207-1217. PubMed ID: 28205038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-Informed Drug Development in Pediatric Dose Selection.
    Bi Y; Liu J; Li F; Yu J; Bhattaram A; Bewernitz M; Li RJ; Ahn J; Earp J; Ma L; Zhuang L; Yang Y; Zhang X; Zhu H; Wang Y
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S60-S69. PubMed ID: 34185906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of Adult Data in Designing Pediatric Pharmacokinetic Studies: How Much Are Historical Adult Data Worth?
    Hsu CH; Steven Xu X; Wang J; Zhang L; Liu C; Wang Y
    J Clin Pharmacol; 2019 Jul; 59(7):989-996. PubMed ID: 30748023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing simple PK-PD studies in children.
    Thomson AH; Elliott HL
    Paediatr Anaesth; 2011 Mar; 21(3):190-6. PubMed ID: 21040154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small sample approach, and statistical and epidemiological aspects.
    Offringa M; van der Lee H
    Handb Exp Pharmacol; 2011; 205():181-202. PubMed ID: 21882112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.
    Mehrotra N; Bhattaram A; Earp JC; Florian J; Krudys K; Lee JE; Lee JY; Liu J; Mulugeta Y; Yu J; Zhao P; Sinha V
    Drug Metab Dispos; 2016 Jul; 44(7):924-33. PubMed ID: 27079249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years.
    Edginton AN; Shah B; Sevestre M; Momper JD
    Clin Pharmacokinet; 2013 Aug; 52(8):693-703. PubMed ID: 23588537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.